The South Korean Dravet Syndrome market is on the cusp of a revolutionary change with the advent of gene therapy. As a monogenic disorder caused by a single gene mutation, Dravet syndrome is an ideal candidate for this groundbreaking treatment approach. Gene therapies, which aim to correct the underlying genetic defect, offer the potential for a one-time, curative treatment, fundamentally altering the long-term prognosis for patients. The South Korea Dravet Syndrome Market report indicates that this is a key area of future growth and investment. The Advanced Regenerative Medicine Law in South Korea, which allows for expanded access to advanced therapies, is a significant enabler of this trend, positioning the country as a leader in this field.

While still in the early stages, the prospect of gene therapy is generating immense hope within the patient community. It could potentially eliminate the need for lifelong medication and its associated side effects, while also improving neurodevelopmental outcomes. The challenges, however, are substantial, including the high cost of these therapies and the need for a robust regulatory and clinical infrastructure. Nevertheless, the market is demonstrating a clear commitment to overcoming these hurdles, driven by the desire to offer a truly transformative solution to families affected by Dravet syndrome.